Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Renal Cell 23Sarcoma 18Neoplasms 8Neoplasm Metastasis 8Breast Neoplasms 8Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Liposarcoma 5Leiomyosarcoma 5Hemangiosarcoma 5Sarcoma, Synovial 4Neurofibrosarcoma 4Lung Neoplasms 4Kidney Neoplasms 4Histiocytoma, Malignant Fibrous 4Urinary Bladder Neoplasms 3Recurrence 3Prostatic Neoplasms 3Glioblastoma 3Thyroid Carcinoma, Anaplastic 2Small Cell Lung Carcinoma 2Sarcoma, Alveolar Soft Part 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Gliosarcoma 2Fibrosarcoma 2Dermatofibrosarcoma 2Clear-cell metastatic renal cell carcinoma 2

Interventions

Docetaxel 2pazopanib 1Gemcitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Histiocytoma × pazopanib × Clear all
NCT01418001 2018-01-11

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
5 enrolled 6 charts
Sarcoma

Leiomyosarcoma, Sarcoma, Neurofibrosarcoma, Histiocytoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡